These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34474079)

  • 1. Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.
    King BA; Mesinkovska NA; Craiglow B; Kindred C; Ko J; McMichael A; Shapiro J; Goh C; Mirmirani P; Tosti A; Hordinsky M; Huang KP; Castelo-Soccio L; Bergfeld W; Paller AS; Mackay-Wiggan J; Glashofer M; Aguh C; Piliang M; Yazdan P; Lo Sicco K; Cassella JV; Koenigsberg J; Ahluwalia G; Ghorayeb E; Fakharzadeh S; Napatalung L; Gandhi K; DeLozier AM; Nunes FP; Senna MM
    J Am Acad Dermatol; 2022 Feb; 86(2):359-364. PubMed ID: 34474079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.
    ; Moussa A; Bennett M; Wall D; Meah N; York K; Bokhari L; Asfour L; Rees H; Abraham LS; Asz-Sigall D; Basmanav FB; Bergfeld W; Betz RC; Bhoyrul B; Blume-Peytavi U; Callender V; Chitreddy V; Combalia A; Cotsarelis G; Craiglow B; Dhurat R; Donovan J; Doroshkevich A; Eisman S; Farrant P; Ferrando J; Gadzhigoroeva A; Green J; Grimalt R; Harries M; Hordinsky M; Irvine A; Jolliffe V; Kaiumov S; King B; Lee J; Lee WS; Li J; Lortkipanidze N; McMichael A; Mesinkovska NA; Messenger A; Mirmirani P; Olsen E; Orlow SJ; Ovcharenko Y; Piraccini BM; Pirmez R; Rakowska A; Reygagne P; Rudnicka L; Corralo DS; Senna M; Shapiro J; Sharma P; Siliuk T; Starace M; Suchonwanit P; Takwale A; Tosti A; Vañó-Galván S; Visser WI; Vogt A; Wade M; Yip L; Zhou C; Sinclair R
    JAMA Dermatol; 2024 Mar; 160(3):341-350. PubMed ID: 38324292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
    Br J Dermatol; 2020 Oct; 183(4):702-709. PubMed ID: 31970750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata.
    Meah N; Wall D; York K; Bhoyrul B; Bokhari L; Asz-Sigall D; Bergfeld WF; Betz RC; Blume-Peytavi U; Callender V; Chitreddy V; Combalia A; Cotsarelis G; Craiglow B; Donovan J; Eisman S; Farrant P; Green J; Grimalt R; Harries M; Hordinsky M; Irvine AD; Itami S; Jolliffe V; King B; Lee WS; McMichael A; Messenger A; Mirmirani P; Olsen E; Orlow SJ; Piraccini BM; Rakowska A; Reygagne P; Roberts JL; Rudnicka L; Shapiro J; Sharma P; Tosti A; Vogt A; Wade M; Yip L; Zlotogorski A; Sinclair RD
    J Am Acad Dermatol; 2021 Jun; 84(6):1594-1601. PubMed ID: 32926985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata.
    Meah N; Wall D; York K; Bhoyrul B; Bokhari L; Sigall DA; Bergfeld WF; Betz RC; Blume-Peytavi U; Callender V; Chitreddy V; Combalia A; Cotsarelis G; Craiglow B; Donovan J; Eisman S; Farrant P; Green J; Grimalt R; Harries M; Hordinsky M; Irvine AD; Itami S; Jolliffe V; King B; Lee WS; McMichael A; Messenger A; Mirmirani P; Olsen E; Orlow SJ; Piraccini BM; Rakowska A; Reygagne P; Roberts JL; Rudnicka L; Shapiro J; Sharma P; Tosti A; Vogt A; Wade M; Yip L; Zlotogorski A; Sinclair R
    J Am Acad Dermatol; 2020 Jul; 83(1):123-130. PubMed ID: 32165196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective outcome measures: Collecting meaningful data on alopecia areata.
    Olsen EA; Roberts J; Sperling L; Tosti A; Shapiro J; McMichael A; Bergfeld W; Callender V; Mirmirani P; Washenik K; Whiting D; Cotsarelis G; Hordinsky M
    J Am Acad Dermatol; 2018 Sep; 79(3):470-478.e3. PubMed ID: 29128463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
    Renert-Yuval Y; Correa da Rosa J; Garcet S; Pavel AB; Bares J; Chima M; Hawkes JE; Gilleaudeau P; Sullivan-Whalen M; Singer GK; Krueger JG; Guttman-Yassky E
    Br J Dermatol; 2022 Oct; 187(4):539-547. PubMed ID: 35656793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Mesinkovska N; Ko JM; King BA
    Qual Life Res; 2023 May; 32(5):1319-1327. PubMed ID: 35821174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Korean Consensus Criteria for the Severity Classification of Alopecia Areata.
    Jang YH; Lee SS; Park DY; Lee Y; Kim DY; Park H; Shin HT; Kim JE; Shin K; Lee JH; Choi JW; Park BC; Kim BJ; Seo SH; Won CH; Park J; Kim MS; Kim SS; Lew BL; Huh CH; Kwon O; Lee YW; Kim MB;
    Ann Dermatol; 2024 Aug; 36(4):236-246. PubMed ID: 39082660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the Scalp Hair Assessment PRO™ measure for alopecia areata.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
    Br J Dermatol; 2020 Dec; 183(6):1065-1072. PubMed ID: 32163589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of alopecia areata: An Australian expert consensus statement.
    Cranwell WC; Lai VW; Photiou L; Meah N; Wall D; Rathnayake D; Joseph S; Chitreddy V; Gunatheesan S; Sindhu K; Sharma P; Green J; Eisman S; Yip L; Jones L; Sinclair R
    Australas J Dermatol; 2019 May; 60(2):163-170. PubMed ID: 30411329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alopecia areata severity index (AASI): A reliable scoring system to assess the severity of alopecia areata on face and scalp-a pilot study.
    Majid I; Sameem F; Sultan J; Aleem S
    J Cosmet Dermatol; 2021 Aug; 20(8):2565-2570. PubMed ID: 34129730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata.
    Aşkın Ö; Yücesoy SN; Coşkun E; Engin B; Serdaroğlu S
    An Bras Dermatol; 2021; 96(5):551-557. PubMed ID: 34281739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS).
    Wall D; Meah N; York K; Bhoyrul B; Bokhari L; Abraham LS; Adams R; Bergfeld W; Betz RC; Blume-Peytavi U; Callender V; Campbell C; Chambers J; Chen G; Chitreddy V; Cotsarelis G; Craiglow B; Dhurat R; Dlova N; Donovan J; Duque-Estrada B; Eisman S; Ellison A; Farrant P; Barberá JF; Gadzhigoroeva A; Grimalt R; Harries M; Hordinsky M; Irvine AD; Jolliffe V; Jones L; King B; Lee WS; Lortkipanidze N; McMichael A; Messenger A; Mirmirani P; Olsen E; Orlow SJ; Ovcharenko Y; Piraccini BM; Pirmez R; Rakowska A; Reygagne P; Riley M; Rudnicka L; Saceda Corralo D; Shapiro J; Sharma P; Silyuk T; Kaiumov S; Tobin DJ; Tosti A; Vañó-Galván S; Vogt A; Wade M; Yip L; Zlotogorski A; Zhou C; Sinclair R
    JAMA Dermatol; 2021 Apr; 157(4):1-11. PubMed ID: 33656556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes.
    Chernyshov PV; Tomas-Aragones L; Finlay AY; Manolache L; Marron SE; Sampogna F; Spillekom-van Koulil S; Pustisek N; Suru A; Evers AWM; Salavastru C; Svensson A; Abeni D; Blome C; Poot F; Jemec GBE; Linder D; Augustin M; Bewley A; Salek SS; Szepietowski JC
    J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1614-1621. PubMed ID: 34107093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-gamma in alopecia areata.
    Arca E; Muşabak U; Akar A; Erbil AH; Taştan HB
    Eur J Dermatol; 2004; 14(1):33-6. PubMed ID: 14965793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of health utility values for alopecia areata.
    Aggio D; Dixon C; Law EH; Randall R; Price T; Lloyd A
    Qual Life Res; 2024 Jun; 33(6):1581-1592. PubMed ID: 38551802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis.
    Peterson DM; Craiglow BG; Mesinkovska NA; Ko J; Senna MM; King BA
    J Am Acad Dermatol; 2022 Nov; 87(5):e149-e151. PubMed ID: 34678234
    [No Abstract]   [Full Text] [Related]  

  • 20. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.